|
|
|
|
| LEADER |
01000caa a22002652c 4500 |
| 001 |
NLM36032004X |
| 003 |
DE-627 |
| 005 |
20250305031154.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231226s2023 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1002/adma.202304620
|2 doi
|
| 028 |
5 |
2 |
|a pubmed25n1200.xml
|
| 035 |
|
|
|a (DE-627)NLM36032004X
|
| 035 |
|
|
|a (NLM)37532257
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Zhang, Liang
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a AIEgen-Based Covalent Organic Frameworks for Preventing Malignant Ventricular Arrhythmias Via Local Hyperthermia Therapy
|
| 264 |
|
1 |
|c 2023
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Revised 02.12.2023
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status Publisher
|
| 520 |
|
|
|a © 2023 Wiley-VCH GmbH.
|
| 520 |
|
|
|a The engineering of aggregation-induced emission luminogens (AIEgen) based covalent organic frameworks (COFs), TDTA-COF, BTDTA-COF, and BTDBETA-COF are reported, as hyperthermia agents for inhibiting the occurrence of malignant ventricular arrhythmias (VAs). These AIE COFs exhibit dual functionality, as they not only directly modulate the function and neural activity of stellate ganglion (SG) through local hyperthermia therapy (LHT) but also induce the browning of white fat and improve the neuroinflammation peri-SG microenvironment, which is favorable for inhibiting ischemia-induced VAs. In vivo studies have confirmed that BTDBETA-COF-mediated LHT enhances thermogenesis and browning-related gene expression, thereby serving a synergistic role in combating VAs. Transcriptome analysis of peri-SG adipose tissue reveals a substantial downregulation of inflammatory cytokines, highlighting the potency of BTDBETA-COF-mediated LHT in ameliorating the neuroinflammation peri-SG microenvironment and offering myocardial and arrhythmia protection. The work on AIE COF-based hyperthermia agent for VAs inhibition provides a new avenue for mitigating cardiac sympathetic nerve hyperactivity
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a AIEgen
|
| 650 |
|
4 |
|a covalent organic frameworks
|
| 650 |
|
4 |
|a hyperthermia agent
|
| 650 |
|
4 |
|a malignant ventricular arrhythmias
|
| 650 |
|
4 |
|a neuromodulation
|
| 700 |
1 |
|
|a Guo, Fuding
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Xu, Saiting
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Deng, Qiang
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Xie, Mengjie
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Sun, Jianwei
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Kwok, Ryan T K
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Lam, Jacky W Y
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Deng, Hexiang
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Jiang, Hong
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Yu, Lilei
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Tang, Ben Zhong
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Advanced materials (Deerfield Beach, Fla.)
|d 1998
|g (2023) vom: 02. Aug., Seite e2304620
|w (DE-627)NLM098206397
|x 1521-4095
|7 nnas
|
| 773 |
1 |
8 |
|g year:2023
|g day:02
|g month:08
|g pages:e2304620
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1002/adma.202304620
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|j 2023
|b 02
|c 08
|h e2304620
|